Redeye: Doro - Product development focus
Redeye observes that Doro's Q2 2023 sales were consistent with our projections, with a beneficial currency effect providing some assistance. The company remains committed to R&D and user research, as these are key strategies to test and innovate new products for future launches. As mentioned in our past updates, these initiatives depress margins in the short run. However, we maintain our belief that the company is setting a course towards achieving positive growth in the subsequent years.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/